Log In
Print this Print this

anti-CX3CR1 Nanobody

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionNanobody against chemokine CX3C motif receptor 1 (CX3CR1)
Molecular Target Chemokine CX3C motif receptor 1 (CX3CR1)
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase I
Standard Indication Renal (unspecified)
Indication DetailsTreat chronic kidney disease (CKD)
Regulatory Designation
PartnerBoehringer Ingelheim GmbH

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today